ArticleFrontiers in oncology2024
Influence of neuropathological diagnosis on psychooncological distress in neurooncological patients - a retrospective cross-sectional analysis.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas, the most common primary brain tumours, are classified based on histology and molecular genetics. Glioblastomas (GBM) are highly aggressive and are graded as WHO grade 4, while astrocytoma and oligodendrogliomas fall under WHO grades 2-3 (4). Gliomas affect 6 per 100,000 people, with a higher incidence in men. GBM has the poorest prognosis, whereas grade 2 astrocytoma and oligodendrogliomas show better outcomes. Quality of life (QoL) is now a crucial therapeutic goal alongside survival. Despite the impact of gliomas on QoL, especially given their incurability and progressive neurological deficits, research specifically comparing QoL and psycho-oncological stress in GBM versus grade 2 gliomas (glioma_2) remains limited. This study aims to fill that gap using validated measurement methods. Methods: This retrospective, single-centre study investigated differences in QoL among neuro-oncological patients using the Karnofsky Performance Score (KPS), Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), and EORTC-QLQ-C30-BN20. Data were collected before chemotherapy or radiotherapy to avoid therapy impact on QoL. Out of 2258 patients screened until June 30, 2022, 639 had glioblastoma or WHO grade 2 gliomas, with 223 meeting inclusion criteria for analysis. Results: The study included 161 GBM and 62 Glioma_2 patients, with 64% of all patients being male. The mean age was 58.11 years (SD ± 16.186). The DT did not show significant differences between GBM and glioma_2 glioma patients (median GBM:6 vs. 5 in glioma_2, p=0.480). However, the HADS-D indicates that GBM patients experience significantly more depression (median GBM 4.5 vs. 4 in glioma_2, p=0.033), though anxiety levels are similar in both groups (median GBM. 6 vs. 6 in glioma_2, p=0.867). The KPS (median GBM 70 vs. 90 in glioma_2, p<0.001) and specific aspects of the EORTC-QLQ-C30-BN20 questionnaire demonstrate that GBM patients have notably greater physical impairments than glioma_2 patients at diagnosis. Overall, GBM patients report worse quality of life compared to glioma_2 patients (median GBM 50 vs. 67 in glioma_2, p<0.001). Conclusion: This study showed that distress is present in glioma patients regardless of their histopathological grading, even though GBM patients show higher depression levels and more physical limitations. Targeted anxiety management and early depression screening are essential for all glioma patients. Early QoL screening and making QoL a therapeutic goal benefits patient care and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.